NMD Pharma A/S’ Post

TREAT-NMD is thrilled to announce our participation at the upcoming Muscular Dystrophy Association Clinical & Scientific Conference in Orlando from March 3-6, 2024 - one of the most exciting events in the NMD calendar! David Allison, Clare Bradley and Kelly Evans will be there on behalf of TREAT-NMD and they would love to chat so please stop them to say hello! As well as attending we are once again proud to be partnering with the Muscular Dystrophy Association (MDA) and the FSHD Society to deliver a CE accredited session for delegates as part of the Clinical Considerations track at the event. The session will be chaired by Jeffrey M. Statland (University of Kansas Medical Center, USA), accompanied by expert clinicians, who will focus on providing 'An Overview of Therapeutics for FSHD'. This collaboration underscores our commitment to advancing knowledge and fostering collaboration within the neuromuscular community. We’d love for you to join (either in person or virtually) to explore the latest advancements, breakthroughs, and clinical considerations in the field of neuromuscular disorders. Together with MDA, we aim to create a platform for insightful discussions and networking opportunities. For more information about the event and to register to attend go to > https://lnkd.in/g9NtQfY #NMDs #NeuromuscularDiseases #NeuromuscularResearch #MDAConference #CollaborationInScience #FSHDeducation #FSHD

We are proud to sponsor Cure SMA’s Annual International Spinal Muscular Atrophy (#SMA) Research & Clinical Care Meeting, the largest gathering of academic researchers, government agencies, #biotech industry representatives and clinicians dedicated to SMA research and care. Held from 5-7 June in Austin, Texas, goals of this year’s meeting include open communication of early scientific data, cross-disciplinary knowledge sharing to accelerate the pace of research and the promotion of #collaboration between the SMA community and researchers. Vera K., our Director of Clinical Development, will present the latest updates from the podium of the Research and Clinical Care Symposium on the ongoing Phase 2 #ClinicalTrial of NMD670, our lead CIC-1 ion channel skeletal muscle-activating therapy, in ‘Study Design and Status Update on the SYNAPSE-SMA Phase 2 Trial of NMD670 in Ambulatory Adults with Spinal Muscular Atrophy’ on 7 June from 11:00-11:20 CDT. NMD Pharma will also be presenting two abstracts detailing the mechanism of action of the skeletal-muscle targeted oral therapy NMD670 at the #2024SMACongress. The abstracts, which include a scientific poster and a ‘family friendly’ research poster, can be viewed from 5 June through 7 June at the meeting. Members of the NMD Pharma team, Dan Brennan, SVP, Corporate and Commercial Strategy, and Caitlin Cornwall, Associate Director of Clinical Operations, will also attend the meeting. If you are interested in learning about our novel muscle-targeted approach the treatment of SMA, please reach out to [email protected] to set up a meeting with them. For more information: https://lnkd.in/dJTQQm8v #NMDPharma #CureSMA #Conference #NeuromuscularDisease #Innovation

We are delighted to announce one of the biggest milestones in our mission to transform chronic wound care — our CLEANVLU Phase IIa clinical trial report, which demonstrates proof-of-concept and safety of Aurase Wound Gel in humans, has now been published in International Wound Journal. Aurase Wound Gel aims to provide, for the first time, a safe, pain-free, and effective treatment for millions of people suffering from chronic wounds worldwide, and we are incredibly excited to be progressing this product through further Phase II studies. Our Chairman of the Board, Andy Weymann, MD, MBA, comments: “The peer-review publication of our Phase IIa data not only provides important validation to enable further Phase II studies, but also highlights the clinical potential of Aurase Wound Gel to treat millions of patients globally safely and effectively, addressing an urgent and unmet medical need. With this excellent data we are now fundraising to support the next phase of SolasCure’s clinical and product development.” Learn more here: https://lnkd.in/d4EbWtYd #WoundCare #ChronicWounds #ClinicalTrials #HealthCare

Join us tomorrow to learn how to use patient-generated data in medical device development!

Missed our March webinar on Dry AMD? Watch the recording now to hear directly from patients about their experiences and insights. Find the webinar recording and full Voice of the Patient report at: https://bit.ly/3YbG8Pk

Are you attending American College of Cardiology's ACC.24 in Atlanta? Be sure to stop by booth 1809 and learn how a 1-hour loading dose of Sotalol IV may potentially shorten patient length of stay and increase bed availability at hospitals.* ACC.24 attendees will be able gain insight into one health system’s experience with Sotalol IV by attending the April 6 poster presentation, “Real-World Comparative Effectiveness and Safety of Intravenous to Oral Sotalol Loading Among Patients with Atrial Arrhythmias”, authored by Keturah Weaver, PharmD, BCPS, Benjamin Heikkinen, PharmD, BCIDP, and Melinda Novak, PharmD. For more information about this poster and the conference program, please visit the ACC.24 website at https://lnkd.in/gkrcJVn. See you in Atlanta! #acc2024 #acc24 *Sotalol IV [package insert]. Chicago, IL: AltaThera Pharmaceuticals; 09/2023.  WARNING: Life Threatening Proarrhythmia. Please see Sotalol IV Highlights of Prescribing Information and full Prescribing Information at sotaloliv.com/pi, including boxed warning, contraindications, and dosing. 

We recently attended the NICE 2023 conference where the challenges the healthcare system is facing were analysed by over 500 people from the life science sector. Only by working together will we make change happen. Read our key takeaways: https://bit.ly/469s5K8

With less than 2 weeks to go there is still time to register for the #WODC conference 23-25 April in Boston, MA. 👋 Our mighty team will be on stage 24 April to discuss, ‘Patient Recruitment for Neurodegenerative and Neuromuscular #ClinicalTrials.’ 🧠 Attendees can hear our Director of Clinical Trial Operations, Jytte van Huijstee, alongside our Patient Navigator, Madeleine Carrier PharmD and Patient Advocate Partner, Terri Ellsworth, as they dissect the benefits of our platform to involve all stakeholders throughout the clinical trial funnel, and how our human-led approach including our Patient Navigators, ensures accurate communication along the full funnel. Another of our experts at #WorldOrphanDrugCongress is Dennis Akkaya our Chief Commerical Officer, who will be at our booth 532 to discuss how the myTomorrows approach is breaking barriers in the clinical trial funnel for all stakeholders from patients and advocacy groups through to BioPharma. Book a. meeting with Dennis here: https://lnkd.in/dPRcrnXd Use code SPK50 for 50% off when registering https://lnkd.in/edzz8riT ▶️ Our roundtable is at 14:15 on Wednesday 24 April. Patient Recruitment for Neurodegenerative and Neuromuscular Clinical Trials. - How to reach more patients: clinical trial agnostic and clinical trial specific approaches. - A Patient Navigators role in the Clinical Trial journey of patients and physicians - Understand how to involve all stakeholders through our platform #RareDisease #OrphanDrug #WODC2024

Why do so many clinical trials fail? This customer story showcases how integrating patient and provider insights from the start can drastically improve outcomes. Discover our approach to designing flexible and robust clinical trial protocols: https://hubs.la/Q02JysSS0

Curious on how to accelerate your clinical development? Check out our upcoming webinar for innovative approaches to keep it on track.